105 related articles for article (PubMed ID: 23645760)
1. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.
Misch M; Czabanka M; Dengler J; Stoffels M; Auf G; Vajkoczy P; Stockhammer F
Anticancer Res; 2013 May; 33(5):2093-8. PubMed ID: 23645760
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
5. D-dimer before chemotherapy might predict venous thromboembolism.
Arpaia G; Carpenedo M; Verga M; Mastrogiacomo O; Fagnani D; Lanfredini M; Milani M; Cimminiello C
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):170-5. PubMed ID: 19276795
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
8. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
9. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
10. Value of D-dimer testing for the exclusion of pulmonary embolism in patients with previous venous thromboembolism.
Le Gal G; Righini M; Roy PM; Sanchez O; Aujesky D; Perrier A; Bounameaux H
Arch Intern Med; 2006 Jan; 166(2):176-80. PubMed ID: 16432085
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
12. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.
Ferroni P; Martini F; Portarena I; Massimiani G; Riondino S; La Farina F; Mariotti S; Guadagni F; Roselli M
Clin Lung Cancer; 2012 Nov; 13(6):482-7. PubMed ID: 22591606
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.
Leal T; Robins HI
Cancer Chemother Pharmacol; 2010 Jan; 65(2):399-401. PubMed ID: 19756604
[TBL] [Abstract][Full Text] [Related]
15. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
16. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Chamberlain MC
Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
[No Abstract] [Full Text] [Related]
18. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A; Magnowska M; Suchy W; Swierczynska J; Zaborowski MP; Gaca M; Nowak-Markwitz E
Target Oncol; 2017 Aug; 12(4):495-503. PubMed ID: 28580507
[TBL] [Abstract][Full Text] [Related]
20. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
Cosmi B; Legnani C; Cini M; Guazzaloca G; Palareti G
Thromb Haemost; 2005 Nov; 94(5):969-74. PubMed ID: 16363238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
